Obermatt
See Similar Stocks →

Daewon Pharmaceutical

KSC:003220 · KR7003220001
PharmaceuticalsSmall

360

46
EV / EBIT30
Price / Owner Earnings87
Owner Earnings Yield1
Dividend Yield81
Price/Sales88
EV / Gross Profit81
Price/Book69
Return on Capital62
Cash Return on Capital55
Return on Equity62
EBIT Margin47
Gross Profitability93
Accruals59
Owner Earnings Margin51
Sales growth36
Profit Growth20
Long-Term EPS Growth12
Reinvestment31
Price momentum41
Debt load22
Refinancing64
Debt Payback1
Liquidity24
Analyst ratings84
Opinion Changes50
Price Target Upside25
Market mood1
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Daewon Pharmaceutical doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Websitedaewonpharm.com/main/index.jsp
ISINKR7003220001
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
Chronic DiseasesPain ManagementRespiratoryNeurologyCentral Nervous SystemOncologyHealth CareManufacturingPharmaceutical

Description

Analysis

Middle-of-the-road

Daewon Pharmaceutical Co., Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 2/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
31
2026

All-time high

39

Mar 2026

All-time low

31

Jun 2026

Average rank

35

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
88
—
—
—
Price/Earnings
50
—
—
—
Price/Book
69
—
—
—
Dividend Yield
81
—
—
—
Value (overall)
88
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Daewon Pharmaceutical with its peers
Towa Pharmaceutical
TYO:4553
50
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Il Dong Pharmaceutical
KSC:249420
53
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
PharmGen Science
KSC:004720
74
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Rohto Pharmaceutical
TYO:4527
81
CountryJapan
IndustryPersonal Products
SizeLarge
Full Stock Analysis →
Whanin Pharm
KSC:016580
99
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →